Anekwe, MD, MPH, Contributor
162,163 Retatrutide (LY-3437943), a novel triple agonist developed by Eli Lilly that targets GLP-1R, GIPR and GCGR, has shown potential in preliminary clinical data for providing excellent blood sugar control and significant weight reduction
If you normally inject on Monday morning at home and you fly west, you can still inject on Monday morning local timethe one-week interval is what matters, not the clock time
Resolves quickly with proper fluid intake but requires ongoing vigilance Serious But Less Common Side Effects The MHRA highlights several serious but less common risks that patients should know about 1 : Gallbladder problems: Including gallstones Pancreatitis: Inflammation of the pancreas, which can require hospitalization Allergic reactions: Can include swelling, rash, and trouble breathing Low blood sugar: Can happen even in non-diabetic patients using GLP-1s for weight loss Hair loss: Some patients report temporary thinning of hair Warnings About Misuse Healthcare professionals are concerned about people using GLP-1 medications inappropriately just for cosmetic weight loss
It calls for proactive hydration counseling and electrolyte monitoring through your care team rather than self-directed changes
This is, simply put, lower volumes